Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Stimusil
AddedFeb 18, 2024
UpdatedJun 18, 2026
Stimusil

Stimusil

StimuSIL develops innovative photobiomodulation therapy devices for safer, effective dermatology treatments.

HQ
Washington, D.C., DC, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

StimuSIL, founded in January 2020 by Pablo Villalba Villar in Washington, D.C., is a medical device company focused on developing advanced photobiomodulation (PBM) therapy technologies. The company's core mission is to create safer and more effective PBM treatments for various dermatological and aesthetic conditions. StimuSIL's proprietary devices aim to deliver PBM across the melanin layer of the skin, enhancing the biostimulatory effects and improving treatment outcomes.

Notable figures associated with StimuSIL include its founder, Pablo Villalba Villar. The company has made significant strides in the medical device industry by pioneering methods for subdermal PBM, which promise to increase both the efficacy and safety of dermatological treatments. StimuSIL's innovative approach has garnered attention and investment from key players in the health tech sector, positioning it as a transformative force in dermatology and aesthetic medicine.

Stimusil - Similar Companies

LumiThera logo

LumiThera

lumithera.com

Stimdia Medical logo

Stimdia Medical

stimdia.com

Photopharmics logo

Photopharmics

photopharmics.com

Blossom Innovations logo

Blossom Innovations

DermBiont logo

DermBiont

dermbiont.com

Lumeda logo

Lumeda

lumedainc.com

StimAire logo

StimAire

stimaire.com

Luma Therapeutics logo

Luma Therapeutics

Soltego logo

Soltego

soltego.com

Stealth Therapeutics logo

Stealth Therapeutics

Thermaquil logo

Thermaquil

thermaquil.com

PhotoThera logo

PhotoThera

Aesthetics Biomedical logo

Aesthetics Biomedical

Strata Skin Sciences logo

Strata Skin Sciences

EmitBio logo

EmitBio

emitbio.com

Stimusil - Quick Facts

Who are Stimusil's competitors?

Companies similar to Stimusil include LumiThera, Stimdia Medical, Photopharmics and Blossom Innovations.

When was Stimusil founded?

Stimusil was founded in 2020.

Where is Stimusil's headquarters located?

Stimusil's headquarters is located in Washington, D.C., DC, US.

When was Stimusil's last funding round?

Stimusil's most recent funding round was for $48.8k (USD) in September 2023.

How much has Stimusil raised to-date?

As of Sep 12, 2023, Stimusil has raised a total of $623.8k (USD).

How many employees does Stimusil have?

Stimusil has 5 employees as of Feb 5, 2024.

Stimusil - Classification

Industry
  • Hardware
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified